Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
universal coronavirus vaccine
- Development stage
- Preclinical
- Lead developer
- Orlance
- Modality
- DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Epidermal
01
Overview
Orlance's universal coronavirus vaccine is a preclinical DNA-based vaccine candidate designed to provide broad protection against multiple coronaviruses, including SARS-CoV, SARS-CoV-2, and MERS-CoV. The vaccine utilizes Orlance's proprietary MACH-1 (Micro-particle Accelerated High-speed) epidermal delivery platform, which uses a "gene gun" to deliver DNA-coated micro-particles directly into the skin's immune-rich layers. This approach aims to induce both robust systemic and mucosal immunity, potentially offering a more durable and cross-reactive defense compared to traditional intramuscular injections. The program is currently in the preclinical discovery and feasibility stage.
- Other names
- Universal CoronavirusUniversal Coronavirus (SARS, SARS-2, MERS)
02
Targets
SARS-CoV-2 spikeN (Nucleocapsid protein)Conserved multi-epitope regions across coronaviruses
Beyond the preview
Go deeper on universal coronavirus vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on universal coronavirus vaccine.